Akebia Therapeutics (AKBA) Cash from Operations Growth (5y) (2018 - 2026)
Akebia Therapeutics (AKBA) Cash from Operations Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.89 Bn | 32.15 Bn | 1.97 Bn |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.06 Bn | 20.90 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.43 Bn | 18.62 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.81 Bn | 16.49 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Akebia Therapeutics | 337.81 Mn | 175.21 Mn | 41.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.41% |
| Dec 31, 2025 | 24.67% |
| Sep 30, 2025 | 24.84% |
| Jun 30, 2025 | -9.70% |
| Mar 31, 2025 | 31.42% |
| Dec 31, 2024 | 45.41% |
| Sep 30, 2024 | -21.14% |
| Jun 30, 2024 | 23.48% |
| Mar 31, 2024 | 32.43% |
| Dec 31, 2023 | 49.98% |
| Sep 30, 2023 | 10.47% |
| Jun 30, 2023 | -16.60% |
| Mar 31, 2023 | 2.91% |
| Dec 31, 2022 | -27.27% |
| Sep 30, 2022 | 21.23% |
| Jun 30, 2022 | -26.65% |
| Mar 31, 2022 | -17.81% |
| Dec 31, 2021 | -21.58% |
| Sep 30, 2021 | -14.78% |
| Jun 30, 2021 | -18.56% |